Endocare Inc

Endocare — CJS Securities 4th Annual "New Ideas" Small Cap Investor Conference 2004

7 slides from Endocare's conference presentation, Aug 17, 2004

  1. Slide 1: Endocare, Inc. CJS Securities 4th Annual "New Ideas" Small Cap Investor Conference

    Slide 1: Endocare, Inc. CJS Securities 4th Annual "New Ideas" Small Cap Investor Conference

    Endocare, Inc. CJS Securities, Inc. 4th Annual "New Ideas" Small Cap Investor Conference August 17, 2004

  2. Slide 2: Company Background

    Slide 2: Company Background

    Company Background Endocare is an innovative public medical device company focused on the development of minimally invasive technologies for tissue & tumor ablation and erectile dysfunction. The Company has a strong intellectual property position for its unique technologies that harnesses the powerf

  3. Slide 3: Cryocare TCAP Procedure (Targeted Ablation of the Prostate)

    Slide 3: Cryocare TCAP Procedure (Targeted Ablation of the Prostate)

    Cryocare TCAP Procedure (Targeted Ablation of the Prostate) Minimally invasive procedure that uses ice to destroy prostate cancer. Requires no radiation beams, no permanent radiation seeds and no radiation exposure. Unique "visualization" of the ice ball under ultrasound unlike other ablation treatm

  4. Slide 4: Technology

    Slide 4: Technology

    Technology - Fully integrated planning, placement and treatment - Designed to be physician user-friendly - Designed to be physician user-friendly - Designed to be physician user-friendly - Designed to be physician user-friendly - Designed to be physician user-friendly - Designed to be physician user

  5. Slide 5: Endocare Management

    Slide 5: Endocare Management

    Endocare Management Craig T. Davenport - CEO & Chairman - Chief Executive Officer since December 2003; Chairman since January 2004 - 1994 to 2003 CEO & Managing Partner of The D.W. Group Private investment company - 1985 to 1993 President & COO of Tokos Medical Corporation (NASDAQ) Medical device ma

  6. Slide 6: Company Highlights

    Slide 6: Company Highlights

    Company Highlights: · Annual growth in procedures 45%+ in markets where overall penetration is less than 3%. Proven & experienced management team. Clinically proven technology in prostate cancer with strong IP positioning and patent protection. $400 million + growing market in prostate cancer. · $75

  7. Slide 7: Closing 2004 & into 2005

    Slide 7: Closing 2004 & into 2005

    Closing 2004 & into 2005 Some of our critical objectives: Remain SEC compliant with our financial reporting. Become compliant with Section 404 of Sarbanes-Oxley legislation by year-end. Get the trading of our stock back on a national exchange. Resolve shareholder lawsuits. Satisfactorily resolve the

Source: SEC EDGAR · 8-K filed Aug 17, 2004

More decks from Endocare Inc